Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1

Clinical trial NCT02650986 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02650986
Sponsor: Roswell Park Cancer Institute
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Fallopian Tube Carcinoma Advanced Malignant Solid Neoplasm Advanced Melanoma Advanced Ovarian Carcinoma Advanced Primary Peritoneal Carcinoma Advanced Synovial Sarcoma Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Fallopian Tube Carcinoma Metastatic Melanoma Metastatic Ovarian Carcinoma Metastatic Primary Peritoneal Carcinoma

Start date: 2017-07-14
Primary completion: 2021-03-04
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.